News & Updates
Showing Multidisciplinary articles
Showing

Survodutide reduces body weight, improves cardiometabolic parameters in people with obesity & T2D
Survodutide, a glucagon receptor–glucagon-like peptide-1 (GLP-1) receptor dual agonist, provides sustained weight loss and improves glycaemic control and other cardiometabolic parameters in individuals with obesity and type 2 diabetes (T2D), primary results of the phase III SYNCHRONIZE-2 trial have shown.

Survodutide preferentially reduces metabolically harmful fat in obesity
Survodutide preferentially reduces metabolically harmful fat while largely preserving lean mass and muscle mass, according to new data from a body composition substudy of the phase III SYNCHRONIZE-1 trial involving adults with obesity without diabetes.

Walnut-based low-carbohydrate diet helps reduce fat in people with central obesity
Adherence to a walnut-based low-carbohydrate diet (w-LCD) results in substantially faster and greater fat reduction over time among individuals with central obesity compared with a high-carbohydrate, low-fat diet (HCD), according to a study.






